Hypoglycemic News and Research

RSS

Osiris provides update on Prochymal Phase 2 trial for type 1 diabetes

Osiris Therapeutics, Inc., today provided an update on its Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in patients with newly diagnosed type 1 diabetes.

4 Jan 2012

Medtronic initiates enrollment in Enlite Sensor study for diabetes

Medtronic, Inc. today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite Sensor, the company's latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes.

From Medtronic 10 Nov 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Penn Nursing experts available to discuss stories on American Diabetes Month

Diabetes specialists at the University of Pennsylvania School of Nursing are available to talk with media for stories on American Diabetes Month.

27 Oct 2011

Aggressive glycemic control does not improve clinical outcomes for diabetic CABG patients

Surgeons from Boston Medical Center (BMC) have found that in diabetic patients undergoing coronary artery bypass graft (CABG) surgery, aggressive glycemic control does not result in any significant improvement of clinical outcomes as compared with moderate control.

28 Sep 2011

The obese can’t help but eat: Study

A new study suggests that brains of people who are obese may be wired differently for impulse control, such as resisting a doughnut when their blood sugar levels drop, compared with people who are not obese.

20 Sep 2011

Study on insect species associated with Tibetan medicinal fungus, O. sinensis

A team of researchers from the Institute of Microbiology, Chinese Academy of Sciences (Xiao-Liang Wang and Yi-Jian Yao), summarized all the available information on the insect species associated with the Tibetan medicinal fungus Ophiocordyceps sinensis through an extensive literature survey and analyzed their relationships with the fungus. The study was published in the open access journal ZooKeys.

9 Sep 2011

Green tea shows promise against two types of tumors, HHS

A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia.

16 Aug 2011

IQWiG finds no differences between two treatment strategies for type 2 diabetes

Whether patients with type 2 diabetes mellitus benefit from attempts to lower their blood glucose levels to near-normal levels through treatment remains an unanswered question. The studies currently available provide indications of a benefit but also of potential harm.

15 Jul 2011

Tips for avoiding heat stroke

As a major heat wave sweeps over the country, the University of Alabama at Birmingham Hospital has already treated one patient for heat stroke and is gearing up for more.

13 Jul 2011

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Generex Biotechnology Corporation today announced preliminary clinical results of two major trials using the Generex Oral-lyn formulation that will be used for registration and marketing.

11 Jul 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

Liraglutide medication can help treat type 1 diabetes

Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.

16 Jun 2011

Closed-loop artificial pancreas could fight against Type 1 diabetes

Engineering researchers at Rensselaer Polytechnic Institute are combining automation techniques from oil refining and other diverse areas to help create a closed-loop artificial pancreas. The device will automatically monitor blood sugar levels and administer insulin to patients with Type 1 diabetes, and aims to remove much of the guesswork for those living with the chronic disease.

8 Jun 2011

Insulin could play a new role in fighting Alzheimer's disease: Research

A low dose of insulin has been found to suppress the expression in the blood of four precursor proteins involved in the pathogenesis of Alzheimer's disease, according to new clinical research by University at Buffalo endocrinologists. The research, published in March online in the Journal of Clinical Endocrinology and Metabolism, suggests that insulin could have a powerful, new role to play in fighting Alzheimer's disease.

1 Apr 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

Optivia Biotechnology, a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters.

1 Feb 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011